Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2008 1
2013 1
2014 1
2015 2
2016 2
2017 1
2020 1
2023 1
2024 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
The following term was not found in PubMed: /
Page 1
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.
Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Vachiery JL, Grünig E, Oudiz RJ, Vonk-Noordegraaf A, White RJ, Blair C, Gillies H, Miller KL, Harris JH, Langley J, Rubin LJ; AMBITION Investigators. Galiè N, et al. N Engl J Med. 2015 Aug 27;373(9):834-44. doi: 10.1056/NEJMoa1413687. N Engl J Med. 2015. PMID: 26308684 Free article. Clinical Trial.
METHODS: In this event-driven, double-blind study, we randomly assigned, in a 2:1:1 ratio, participants with World Health Organization functional class II or III symptoms of pulmonary arterial hypertension who had not previously received treatment to receive initial combination t …
METHODS: In this event-driven, double-blind study, we randomly assigned, in a 2:1:1 ratio, participants with World Health Organization funct …
Ambrisentan, an endothelin receptor type A-selective antagonist, inhibits cancer cell migration, invasion, and metastasis.
Kappes L, Amer RL, Sommerlatte S, Bashir G, Plattfaut C, Gieseler F, Gemoll T, Busch H, Altahrawi A, Al-Sbiei A, Haneefa SM, Arafat K, Schimke LF, Khawanky NE, Schulze-Forster K, Heidecke H, Kerstein-Staehle A, Marschner G, Pitann S, Ochs HD, Mueller A, Attoub S, Fernandez-Cabezudo MJ, Riemekasten G, Al-Ramadi BK, Cabral-Marques O. Kappes L, et al. Sci Rep. 2020 Sep 28;10(1):15931. doi: 10.1038/s41598-020-72960-1. Sci Rep. 2020. PMID: 32985601 Free PMC article.
Here, we investigated the in vitro and in vivo anti-tumor effects of the FDA-approved ETAR antagonist, Ambrisentan, which is currently used to treat patients with pulmonary arterial hypertension. ...Taken together, our work suggests a new therapeutic application for Amb …
Here, we investigated the in vitro and in vivo anti-tumor effects of the FDA-approved ETAR antagonist, Ambrisentan, which is currentl …
Safety and effectiveness of ambrisentan in real clinical practice in pulmonary arterial hypertension: Results from the Korean post-marketing surveillance.
Jeon K, Yoo SB, Lee Y, Lee EB, Kim HK, Chang HJ, Chang SA. Jeon K, et al. Pharmacoepidemiol Drug Saf. 2023 Dec;32(12):1387-1394. doi: 10.1002/pds.5671. Epub 2023 Jul 27. Pharmacoepidemiol Drug Saf. 2023. PMID: 37501534
CONCLUSION: In real-world practice, ambrisentan demonstrated tolerable safety and favorable effectiveness in PAH patients in Korea. Age and concomitant drug use can affect the occurrence of AE....
CONCLUSION: In real-world practice, ambrisentan demonstrated tolerable safety and favorable effectiveness in PAH patients in Korea. A …
Long-term safety and tolerability of ambrisentan treatment for pediatric patients with pulmonary arterial hypertension: An open-label extension study.
Ivy D, Beghetti M, Juaneda-Simian E, Ravindranath R, Lukas MA, Machlitt-Northen S, Scott N, Narita J, Berger RMF. Ivy D, et al. Eur J Pediatr. 2024 May;183(5):2141-2153. doi: 10.1007/s00431-024-05446-1. Epub 2024 Feb 16. Eur J Pediatr. 2024. PMID: 38366267 Free PMC article. Clinical Trial.

This open-label, extension study assessed long-term safety, tolerability, and efficacy of ambrisentan in a pediatric population (age 8- < 18 years) with pulmonary arterial hypertension (PAH). ...Most participants received concomitant phosphodiesterase-5 inhibitors (n =

…
This open-label, extension study assessed long-term safety, tolerability, and efficacy of ambrisentan in a pediatric population (age …
Evaluation of efficacy, safety and tolerability of Ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study.
Huo Y, Jing ZC, Zeng XF, Liu JM, Yu ZX, Zhang GC, Li Y, Wang Y, Ji QS, Zhu P, Wu BX, Zheng Y, Wang PP, Li J. Huo Y, et al. BMC Cardiovasc Disord. 2016 Oct 22;16(1):201. doi: 10.1186/s12872-016-0361-9. BMC Cardiovasc Disord. 2016. PMID: 27770771 Free PMC article. Clinical Trial.
This open label study assessed the efficacy and safety of ambrisentan in Chinese subjects with PAH. METHODS: Eligible patients with PAH (World Health Organisation [WHO] functional class [FC] II orIII) were enrolled and received Ambrisentan (5 mg) once daily for a 12 …
This open label study assessed the efficacy and safety of ambrisentan in Chinese subjects with PAH. METHODS: Eligible patients with P …
Gateways to clinical trials.
Bayés M, Rabasseda X, Prous JR. Bayés M, et al. Methods Find Exp Clin Pharmacol. 2004 Oct;26(8):639-63. Methods Find Exp Clin Pharmacol. 2004. PMID: 15605126
This issue focuses on the following selection of drugs: Abiraterone acetate, Ad5CMV-p53, adefovir dipivoxil, AE-941, ambrisentan, aripiprazole, atomoxetine hydrochloride, atrasentan; BCH-10618, bimatoprost, BMS-184476, BMS-275183, BMS-387032, botulinum toxin type B, …
This issue focuses on the following selection of drugs: Abiraterone acetate, Ad5CMV-p53, adefovir dipivoxil, AE-941, ambrisentan …
Gateways to clinical trials.
Moral MA, Tomillero A. Moral MA, et al. Methods Find Exp Clin Pharmacol. 2008 Mar;30(2):149-71. Methods Find Exp Clin Pharmacol. 2008. PMID: 18560631
This issue focuses on the following selection of drugs: 131-I-Chlorotoxin, 423557; Abatacept, Ad.Egr.TNF.11D, Adalimumab, AE-941, Ambrisentan, AMR-001, Anacetrapib, Anakinra, Aripiprazole, Atazanavir sulfate; BAY-639044, Bazedoxifene acetate, Belimumab, Bevacizumab, …
This issue focuses on the following selection of drugs: 131-I-Chlorotoxin, 423557; Abatacept, Ad.Egr.TNF.11D, Adalimumab, AE-941, …
Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.
Coghlan JG, Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, Kuwana M, McLaughlin VV, Peacock AJ, Simonneau G, Vachiéry JL, Blair C, Gillies H, Miller KL, Harris JHN, Langley J, Rubin LJ; AMBITION investigators. Coghlan JG, et al. Ann Rheum Dis. 2017 Jul;76(7):1219-1227. doi: 10.1136/annrheumdis-2016-210236. Epub 2016 Dec 30. Ann Rheum Dis. 2017. PMID: 28039187 Free PMC article. Clinical Trial.
OBJECTIVE: To explore the safety and efficacy of initial combination therapy with ambrisentan and tadalafil versus ambrisentan or tadalafil monotherapy in patients with CTD-PAH and SSc-PAH enrolled in the AMBITION trial. ...Treatment-naive patients were randomised 2 …
OBJECTIVE: To explore the safety and efficacy of initial combination therapy with ambrisentan and tadalafil versus ambrisentan …
[Efficiency of initiation with ambrisentan versus bosentan in the treatment of pulmonary arterial hypertension].
Villa G, Morano R, Román A, Gil J. Villa G, et al. Farm Hosp. 2013 Sep-Oct;37(5):358-65. doi: 10.7399/FH.2013.37.5.736. Farm Hosp. 2013. PMID: 24128097 Spanish.
RESULTS: No clinically relevant differences in QALY per-patient and year were found for initiation with ambrisentan and bosentan: 0.6853 and 0.6902, respectively. Initiation with ambrisentan resulted in lower pharmacological treatment and AE management costs: …
RESULTS: No clinically relevant differences in QALY per-patient and year were found for initiation with ambrisentan and bosentan: 0.6 …
Multiple compound-related adverse properties contribute to liver injury caused by endothelin receptor antagonists.
Kenna JG, Stahl SH, Eakins JA, Foster AJ, Andersson LC, Bergare J, Billger M, Elebring M, Elmore CS, Thompson RA. Kenna JG, et al. J Pharmacol Exp Ther. 2015 Feb;352(2):281-90. doi: 10.1124/jpet.114.220491. Epub 2014 Dec 2. J Pharmacol Exp Ther. 2015. PMID: 25467130
Drug-induced liver injury has been observed in patients treated with the endothelin receptor antagonists sitaxentan and bosentan, but not following treatment with ambrisentan. The aim of our studies was to assess the possible role of multiple contributory mechanisms in thi …
Drug-induced liver injury has been observed in patients treated with the endothelin receptor antagonists sitaxentan and bosentan, but not fo …